CArdiac STereotactic Radiation Treatment for Ablation of ventRicular Tachycardia
NCT07931014, Not applicable, Recruiting, Cancer Research Antwerp
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | CArdiac STereotactic Radiation Treatment for Ablation of ventRicular Tachycardia | ClinicalTrials.gov |
| NCT number | NCT07931014 | ClinicalTrials.gov |
| Status | Recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 20 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Cancer Research Antwerp | ClinicalTrials.gov |
| Conditions | Ventricular Tachycardia | ClinicalTrials.gov |
| Interventions | Stereotactic body radiation therapy (SBRT) | ClinicalTrials.gov |
| First posted | 2026-11-12 | ClinicalTrials.gov |
| Last updated | 2026-11-12 | ClinicalTrials.gov |
Registered outcomes 15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Feasibility of SBRT for the treatment of ventricular tachycardia | Day of SBRT treatment (Day 1) | Feasibility will be assessed as the successful implementation and completion of cardiac SBRT without interruption of treatment. SBRT consists of a single fraction of 25 Gy delivered to the ventricular tachycardia target. | ClinicalTrials.gov |
| Primary | Safety of SBRT for the treatment of ventricular tachycardia. | From SBRT treatment through 31 days after SBRT | Safety will be assessed by the incidence and severity of adverse events related to radiotherapy following cardiac SBRT. Adverse events will be assessed and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0. | ClinicalTrials.gov |
| Secondary | Change in ventricular tachycardia burden following SBRT | 6 months before SBRT through 6 months after SBRT | The ventricular tachycardia (VT) burden will be assessed by the number of VT episodes recorded by ECG and implantable cardioverter-defibrillator (ICD) readouts. The number of VT episodes during the 6 months following SBRT will be compared with the number during the 6 months preceding SBRT. A 6-week blanking period immediately following SBRT will be taken into account in the analysis of VT recurrences. | ClinicalTrials.gov |
| Secondary | Time from SBRT to first VT recurrence | From SBRT through 36 months after treatment | Time from SBRT treatment to the first documented recurrence of ventricular tachycardia, as determined from ICD readouts. A 6-week blanking period following SBRT will be considered in the analysis of VT recurrence. | ClinicalTrials.gov |
| Secondary | Time from SBRT to first sustained ventricular tachycardia or ICD shock | From SBRT through 36 months after treatment | Time from SBRT treatment to the first occurrence of sustained ventricular tachycardia or the first appropriate ICD shock during follow-up. | ClinicalTrials.gov |
| Secondary | Time from SBRT to first ventricular tachycardia storm | From SBRT through 36 months after treatment | Time from SBRT treatment to the first occurrence of a ventricular tachycardia storm during follow-up. | ClinicalTrials.gov |
| Secondary | Change in the number of electrical storms following SBRT | 6 months before SBRT through 6 months after SBRT | The number of electrical storms occurring following SBRT will be compared with the number occurring before SBRT treatment. | ClinicalTrials.gov |
| Secondary | Change in anti-tachycardia pacing and ICD shocks following SBRT | 6 months before SBRT through 6 months after SBRT | The number of anti-tachycardia pacing (ATP) interventions and ICD shocks following SBRT will be compared with the number occurring before SBRT treatment. | ClinicalTrials.gov |
| Secondary | Change in anti-arrhythmic medication use following SBRT | From baseline through 36 months after SBRT | Anti-arrhythmic medication use will be assessed during follow-up. The type and dosage of anti-arrhythmic drugs will be collected to evaluate changes in the need for anti-arrhythmic treatment following SBRT. | ClinicalTrials.gov |
| Secondary | Overall survival following SBRT | From SBRT through 36 months after treatment | Overall survival will be assessed from the date of SBRT treatment until death from any cause. | ClinicalTrials.gov |
| Secondary | Incidence of heart transplantation following SBRT | From SBRT through 36 months after treatment | The number and proportion of participants requiring heart transplantation during follow-up will be assessed. | ClinicalTrials.gov |
| Secondary | Incidence of cardiac arrhythmic mortality following SBRT | From SBRT through 36 months after treatment | The number and proportion of participants who die from a cardiac arrhythmic cause during follow-up will be assessed. | ClinicalTrials.gov |
| Secondary | Incidence of cardiac non-arrhythmic mortality following SBRT | From SBRT through 36 months after treatment | The number and proportion of participants who die from a cardiac non-arrhythmic cause during follow-up will be assessed. | ClinicalTrials.gov |
| Secondary | Incidence and severity of acute radiation-related adverse events | Through 90 days after SBRT | The incidence and severity of adverse events related to radiotherapy will be assessed and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0. Acute adverse events are defined according to the time period specified in the protocol. | ClinicalTrials.gov |
| Secondary | Incidence and severity of late radiation-related adverse events | The protocol defines late adverse events as those occurring more than 90 days after starting radiotherapy. | The incidence and severity of late adverse events related to radiotherapy will be assessed and graded according to NCI CTCAE version 5.0. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.3.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 4a570df2e7274cee2d4fa2959402fab41880e2cd412e4b590390035fbea69391 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
Release trials-2026-11-12-0.3.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.